TRANSCODE THERAPEUTICS, INC.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers

The RNA Oncology Company​™

Rapidly Advancing New Scientific Discoveries

​​to Transform the Way Cancer is Treated Using RNA

TransCode is developing RNA therapeutics for the treatment of several tumor indications with its initial focus on tackling one of the most feared stages of cancer -- cancer progression or metastasis.
Click on the animation above to see how our lead candidate therapeutic works

Power and Potential of RNA-based Therapies

The power of RNA therapeutics lies in their ability to target any gene which enables rational and straightforward drug design. RNA-based therapeutics are highly selective to their targets, potentially making available a broad array of previously undruggable targets in cancer including metastasis.
Read More

​TransCode Therapeutics believes it has overcome the barrier to harnessing
​RNA technology for cancer treatment — delivery of RNA therapeutics to cancer cells

Picture
A small, non-coding microRNA called miRNA-10b, is shown to be the master regulator of metastasis in a range of solid tumors

Picture
Metastatic tumor cells are better equipped to safely travel to other parts of the body and develop metastases in organs different from the organ of origin
Picture
Cells in the primary tumor are known to upregulate miRNA-10b which allows metastatic cells to develop, detach, and migrate

Picture
TransCode’s TTX platform has the potential to treat a variety of
​tumor indications through effective delivery and targeting
Read More
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

About

About
leadership

Partnering
​Careers     

Focus

Focus

Science

Science
​Resources

Pipeline

PIPELINE
TTX-MC138
​OTHER CANDIDATES

Contact/Support

Contact
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2022.​ ALL RIGHTS RESERVED.
  • Home
  • About
    • Who We Are
    • Leadership
    • Partnering
  • Focus
  • Science
  • Pipeline
    • Platform
    • TTX-MC138
    • Other Candidates
  • Resources
  • Investors
  • Careers